AGIO EBITDA | AGIOS PHARMACEUTICALS, INC.

AGIOS PHARMACEUTICALS, INC. (AGIO) EBITDA

2026-06-30: Basis Reported; EBITDA (m); Operating income -$110.55M; Depreciation and amortization (m).
2026-03-31: Basis Reported; EBITDA (m); Operating income -$110.03M; Depreciation and amortization (m).
2025-09-30: Basis Reported; EBITDA (m); Operating income -$116.87M; Depreciation and amortization (m).
2025-06-30: Basis Reported; EBITDA (m); Operating income -$127.06M; Depreciation and amortization (m).

Complete source-backed ebitda history.

Available history: 2017-12-31 to 2019-12-31
Data captured: 2026-09-04

Historical EBITDA

EBITDA 3 month

Date	Basis	EBITDA	Operating income	Depreciation and amortization	Revenue	EBITDA margin	Capital spending	Operating cash flow	Cost of products and services	Research and development	Selling, general and administration	Income tax expense / benefit
2026-06-30	Reported	(m)	-$110.55M	(m)	$44.74M	(m)	$1.21M*	-$57.31M*	$3.00M	$100.75M	$51.55M	(m)
2026-03-31	Reported	(m)	-$110.03M	(m)	$20.75M	(m)	$769.00K	-$118.92M	$1.32M	$81.15M	$48.30M	(m)
2025-09-30	Reported	(m)	-$116.87M	(m)	$12.88M	(m)	$1.55M*	-$88.15M*	$1.68M	$86.80M	$41.27M	$0.00
2025-06-30	Reported	(m)	-$127.06M	(m)	$12.46M	(m)	$875.00K*	-$77.12M*	$1.70M	$91.94M	$45.87M	(m)
2025-03-31	Reported	(m)	-$106.63M	(m)	$8.73M	(m)	$766.00K	-$111.49M	$1.08M	$72.74M	$41.53M	(m)
2024-09-30	Reported	(m)	-$102.81M	(m)	$8.96M	(m)	$419.00K*	-$84.22M*	$783.00K	$72.45M	$38.54M	$53.12M
2024-06-30	Reported	(m)	-$105.82M	(m)	$8.62M	(m)	$158.00K*	-$72.59M*	$1.50M	$77.40M	$35.54M	(m)
2024-03-31	Reported	(m)	-$92.07M	(m)	$8.19M	(m)	$141.00K	-$99.87M	$627.00K	$68.62M	$31.01M	(m)
2023-09-30	Reported	(m)	-$100.90M	(m)	$7.40M	(m)	$369.00K*	-$61.64M*	$633.00K	$81.84M	$25.82M	$0.00
2023-06-30	Reported	(m)	-$93.70M	(m)	$6.71M	(m)	-$3.00K*	-$66.75M*	$1.11M	$68.89M	$30.41M	(m)
2023-03-31	Reported	(m)	-$90.61M	(m)	$5.61M	(m)	$399.00K	-$95.18M	$554.00K	$67.30M	$28.37M	(m)
2022-09-30	Reported	(m)	-$91.09M	(m)	$3.52M	(m)	$38.00K*	-$71.35M*	$517.00K	$64.97M	$29.12M	$0.00
2022-06-30	Reported	(m)	-$97.64M	(m)	$5.58M	(m)	$1.93M*	-$74.23M*	$435.00K	$74.52M	$28.26M	$0.00
2022-03-31	Reported	(m)	-$101.14M	(m)	$832.00K	(m)	$2.80M	-$97.73M	$339.00K	$70.12M	$31.52M	$0.00
2021-09-30	Reported	(m)	-$91.15M	(m)	$0.00	(m)	-$22.00K*	-$85.18M*	$0.00	$64.00M	(m)	$0.00
2021-06-30	Reported	(m)	-$91.22M	(m)	$0.00	(m)	$249.00K*	-$117.29M*	$0.00	$62.01M	(m)	$0.00
2021-03-31	Reported	(m)	-$91.22M	(m)	$0.00	(m)	$1.01M	-$120.75M	$0.00	$57.67M	(m)	$0.00
2020-12-31	Reported	(m)	-$92.43M	(m)	$44.05M	(m)	(m)	(m)	(m)	(m)	(m)	(m)
2020-09-30	Reported	(m)	-$80.29M	(m)	$34.71M	(m)	$5.20M*	-$68.21M*	$638.00K	$51.94M	(m)	$0.00
2020-06-30	Reported	(m)	-$83.26M	(m)	$37.35M	(m)	$4.14M*	-$67.80M*	$675.00K	$54.09M	(m)	$0.00
2020-03-31	Reported	(m)	-$87.03M	(m)	$87.10M	(m)	$4.20M	-$105.36M	$533.00K	$55.36M	(m)	$0.00
2019-12-31	Reported	(m)	-$105.93M	(m)	$35.44M	(m)	(m)	(m)	(m)	(m)	(m)	(m)
2019-09-30	Reported	(m)	-$109.06M	(m)	$26.02M	(m)	$2.04M*	-$85.59M*	$393.00K	$101.67M	(m)	(m)
2019-06-30	Reported	(m)	-$113.86M	(m)	$26.22M	(m)	$1.27M*	-$88.15M*	$303.00K	$107.39M	(m)	(m)
2019-03-31	Reported	(m)	-$97.48M	(m)	$30.23M	(m)	$2.04M	-$103.27M	$334.00K	$95.58M	(m)	(m)
2018-12-31	Reported	(m)	-$96.36M	(m)	$30.01M	(m)	(m)	(m)	(m)	(m)	(m)	(m)
2018-09-30	Reported	(m)	-$99.16M	(m)	$15.20M	(m)	$3.14M*	-$63.84M*	$695.00K	$82.56M	(m)	(m)
2018-06-30	Reported	(m)	-$72.95M	(m)	$40.41M	(m)	$1.36M*	-$67.39M*	$0.00	$86.73M	(m)	(m)
2018-03-31	Reported	(m)	-$94.01M	(m)	$8.76M	(m)	$1.43M	-$99.00M	$0.00	$78.22M	(m)	(m)
2017-12-31	Reported	(m)	-$90.13M	(m)	(m)	(m)	(m)	(m)	(m)	(m)	(m)	(m)
2017-09-30	Reported	(m)	-$79.02M	(m)	$11.36M	(m)	$2.02M*	-$77.72M*	$0.00	$72.92M	(m)	(m)
2017-06-30	Reported	(m)	-$84.60M	(m)	(m)	(m)	$1.03M*	-$58.99M*	(m)	$79.82M	(m)	(m)
2017-03-31	Reported	(m)	-$67.05M	(m)	(m)	(m)	$293.00K	-$74.07M	(m)	$62.73M	(m)	$0.00
2016-12-31	Reported	(m)	-$57.41M	(m)	(m)	(m)	(m)	(m)	(m)	(m)	(m)	(m)
2016-09-30	Reported	(m)	-$63.51M	(m)	(m)	(m)	$3.43M*	-$49.03M*	(m)	$60.64M	(m)	$0.00
2016-06-30	Reported	(m)	-$56.47M	(m)	(m)	(m)	$2.73M*	(m)	(m)	$50.80M	(m)	$0.00
2016-03-31	Reported	(m)	-$23.59M	(m)	(m)	(m)	$2.53M	(m)	(m)	$44.04M	(m)	$0.00
2015-12-31	Reported	(m)	-$40.90M	(m)	(m)	(m)	(m)	(m)	(m)	(m)	(m)	(m)
2015-09-30	Reported	(m)	-$40.48M	(m)	(m)	(m)	$3.30M*	(m)	(m)	$36.03M	(m)	$0.00
2015-06-30	Reported	(m)	-$32.13M	(m)	(m)	(m)	$10.88M*	(m)	(m)	$36.42M	(m)	$0.00
2015-03-31	Reported	(m)	-$5.20M	(m)	(m)	(m)	$3.80M	(m)	(m)	$32.44M	(m)	$0.00
2014-12-31	Reported	(m)	-$26.73M	(m)	(m)	(m)	(m)	(m)	(m)	(m)	(m)	(m)
2014-09-30	Reported	(m)	$3.21M	(m)	(m)	(m)	$628.00K*	(m)	(m)	$25.53M	(m)	-$448.00K
2014-06-30	Reported	(m)	-$18.33M	(m)	(m)	(m)	$86.00K*	(m)	(m)	$22.58M	(m)	$0.00
2014-03-31	Reported	(m)	-$12.28M	(m)	(m)	(m)	$13.00K	(m)	(m)	$17.41M	(m)	$0.00
2013-12-31	Reported	(m)	-$12.24M	(m)	(m)	(m)	(m)	(m)	(m)	(m)	(m)	(m)
2013-09-30	Reported	(m)	-$11.07M	(m)	(m)	(m)	$99.00K*	-$14.98M*	(m)	$14.80M	(m)	$121.00K
2013-06-30	Reported	(m)	-$8.53M	(m)	(m)	(m)	$701.00K*	(m)	(m)	$12.96M	(m)	$99.00K
2013-03-31	Reported	(m)	-$7.05M	(m)	(m)	(m)	$275.00K	(m)	(m)	$11.46M	(m)	$190.00K
2012-12-31	Reported	(m)	-$6.50M	(m)	(m)	(m)	(m)	(m)	(m)	(m)	(m)	(m)
2012-09-30	Reported	(m)	-$5.11M	(m)	(m)	(m)	$1.14M*	-$11.40M*	(m)	$9.80M	(m)	-$452.00K
2012-06-30	Reported	(m)	-$6.12M	(m)	(m)	(m)	(m)	(m)	(m)	$10.46M	(m)	-$588.00K
2012-03-31	Reported	(m)	-$5.26M	(m)	(m)	(m)	(m)	(m)	(m)	(m)	(m)	(m)

EBITDA 12 month

Date	Basis	EBITDA	Operating income	Depreciation and amortization	Revenue	EBITDA margin	Capital spending	Operating cash flow	Cost of products and services	Research and development	Selling, general and administration	Income tax expense / benefit
2025-12-31	Reported	(m)	-$472.13M	(m)	$54.03M	(m)	$4.32M	-$372.98M	$6.34M	$339.54M	$180.28M	-$1.02M
2024-12-31	Reported	(m)	-$425.74M	(m)	$36.50M	(m)	$1.69M	-$389.84M	$4.17M	$301.29M	$156.78M	$44.24M
2023-12-31	Reported	(m)	-$391.49M	(m)	$26.82M	(m)	$999.00K	-$296.06M	$2.88M	$295.53M	$119.90M	$0.00
2022-12-31	Reported	(m)	-$389.05M	(m)	$14.24M	(m)	$4.88M	-$309.48M	$1.70M	$279.91M	$121.67M	$0.00
2021-12-31	Reported	(m)	-$378.42M	(m)	$0.00	(m)	$5.74M	-$407.32M	$0.00	$256.97M	$121.44M	(m)
2021-09-30	Rolling	(m)	-$366.02M*	(m)	$44.05M*	(m)	(m)	(m)	(m)	(m)	(m)	(m)
2021-06-30	Rolling	(m)	-$355.16M*	(m)	$78.75M*	(m)	(m)	(m)	(m)	(m)	(m)	(m)
2021-03-31	Rolling	(m)	-$347.20M*	(m)	$116.10M*	(m)	(m)	(m)	(m)	(m)	(m)	(m)
2020-12-31	Reported	(m)	-$335.92M	(m)	$0.00	(m)	$14.11M	-$290.76M	$0.00	$220.81M	$115.11M	(m)
2020-12-31	Rolling	(m)	-$343.02M*	(m)	$203.20M*	(m)	(m)	(m)	(m)	(m)	(m)	(m)
2020-09-30	Rolling	(m)	-$356.51M*	(m)	$194.59M*	(m)	(m)	(m)	(m)	(m)	(m)	(m)
2020-06-30	Rolling	(m)	-$385.28M*	(m)	$185.91M*	(m)	(m)	(m)	(m)	(m)	(m)	(m)
2020-03-31	Rolling	(m)	-$415.88M*	(m)	$174.78M*	(m)	(m)	(m)	(m)	(m)	(m)	(m)
2019-12-31	Reported	-$308.18M	(m)	(m)	(m)	(m)	$12.03M	-$370.62M	$1.32M	$214.26M	$102.01M	$0.00
2019-12-31	Rolling	(m)	-$426.33M*	(m)	$117.91M*	(m)	(m)	(m)	(m)	(m)	(m)	(m)
2019-09-30	Rolling	(m)	-$416.76M*	(m)	$112.48M*	(m)	(m)	(m)	(m)	(m)	(m)	(m)
2019-06-30	Rolling	(m)	-$406.86M*	(m)	$101.66M*	(m)	(m)	(m)	(m)	(m)	(m)	(m)
2019-03-31	Rolling	(m)	-$365.95M*	(m)	$115.85M*	(m)	(m)	(m)	(m)	(m)	(m)	(m)
2018-12-31	Reported	-$355.31M	(m)	(m)	(m)	(m)	$6.99M	-$304.42M	$1.40M	$341.32M	$114.14M	$0.00
2018-12-31	Rolling	(m)	-$362.48M*	(m)	$94.39M*	(m)	(m)	(m)	(m)	(m)	(m)	(m)
2018-09-30	Rolling	(m)	-$356.25M*	(m)	(m)	(m)	(m)	(m)	(m)	(m)	(m)	(m)
2018-06-30	Rolling	(m)	-$336.11M*	(m)	(m)	(m)	(m)	(m)	(m)	(m)	(m)	(m)
2018-03-31	Rolling	(m)	-$347.76M*	(m)	(m)	(m)	(m)	(m)	(m)	(m)	(m)	(m)
2017-12-31	Reported	-$314.36M	(m)	(m)	(m)	(m)	$4.63M	-$285.23M	$0.00	$292.68M	$71.12M	$0.00
2017-12-31	Rolling	(m)	-$320.79M*	(m)	(m)	(m)	(m)	(m)	(m)	(m)	(m)	(m)
2017-09-30	Rolling	(m)	-$288.07M*	(m)	(m)	(m)	(m)	(m)	(m)	(m)	(m)	(m)
2017-06-30	Rolling	(m)	-$272.57M*	(m)	(m)	(m)	(m)	(m)	(m)	(m)	(m)	(m)
2017-03-31	Rolling	(m)	-$244.44M*	(m)	(m)	(m)	(m)	(m)	(m)	(m)	(m)	(m)
2016-12-31	Reported	(m)	-$200.99M	(m)	$69.89M	(m)	$9.91M	$38.56M	$0.00	$220.16M	$50.71M	$0.00
2016-12-31	Rolling	(m)	-$200.99M*	(m)	(m)	(m)	(m)	(m)	(m)	(m)	(m)	(m)
2016-09-30	Rolling	(m)	-$184.47M*	(m)	(m)	(m)	(m)	(m)	(m)	(m)	(m)	(m)
2016-06-30	Rolling	(m)	-$161.44M*	(m)	(m)	(m)	(m)	(m)	(m)	(m)	(m)	(m)
2016-03-31	Rolling	(m)	-$137.10M*	(m)	(m)	(m)	(m)	(m)	(m)	(m)	(m)	(m)
2015-12-31	Reported	(m)	-$118.70M	(m)	(m)	(m)	$20.16M	-$76.95M	(m)	$141.83M	(m)	$0.00
2015-12-31	Rolling	(m)	-$118.70M*	(m)	(m)	(m)	(m)	(m)	(m)	(m)	(m)	(m)
2015-09-30	Rolling	(m)	-$104.53M*	(m)	(m)	(m)	(m)	(m)	(m)	(m)	(m)	(m)
2015-06-30	Rolling	(m)	-$60.85M*	(m)	(m)	(m)	(m)	(m)	(m)	(m)	(m)	(m)
2015-03-31	Rolling	(m)	-$47.04M*	(m)	(m)	(m)	(m)	(m)	(m)	(m)	(m)	(m)
2014-12-31	Reported	(m)	-$54.13M	(m)	(m)	(m)	$2.22M	(m)	(m)	$100.37M	(m)	-$426.00K
2014-12-31	Rolling	(m)	-$54.13M*	(m)	(m)	(m)	(m)	(m)	(m)	(m)	(m)	(m)
2014-09-30	Rolling	(m)	-$39.65M*	(m)	(m)	(m)	(m)	(m)	(m)	(m)	(m)	(m)
2014-06-30	Rolling	(m)	-$53.92M*	(m)	(m)	(m)	(m)	(m)	(m)	(m)	(m)	(m)
2014-03-31	Rolling	(m)	-$44.12M*	(m)	(m)	(m)	(m)	(m)	(m)	(m)	(m)	(m)
2013-12-31	Reported	(m)	-$38.88M	(m)	(m)	(m)	$1.29M	-$56.40M	(m)	$54.50M	(m)	$579.00K
2013-12-31	Rolling	(m)	-$38.88M*	(m)	(m)	(m)	(m)	(m)	(m)	(m)	(m)	(m)
2013-09-30	Rolling	(m)	-$33.14M*	(m)	(m)	(m)	(m)	(m)	(m)	(m)	(m)	(m)
2013-06-30	Rolling	(m)	-$27.18M*	(m)	(m)	(m)	(m)	(m)	(m)	(m)	(m)	(m)
2013-03-31	Rolling	(m)	-$24.78M*	(m)	(m)	(m)	(m)	(m)	(m)	(m)	(m)	(m)
2012-12-31	Reported	(m)	-$23.00M	(m)	(m)	(m)	$1.48M	-$49.55M	(m)	$41.04M	(m)	-$2.82M
2012-12-31	Rolling	(m)	-$23.00M*	(m)	(m)	(m)	(m)	(m)	(m)	(m)	(m)	(m)
2011-12-31	Reported	(m)	-$16.63M	(m)	(m)	(m)	$1.91M	-$15.22M	(m)	$31.25M	(m)	$7.21M

Similar stocks

Stock Name	Country	Market Cap	PE Ratio
Sarepta Therapeutics, Inc. (SRPT)	United States	$1.941B	-13.89
Biohaven Ltd. (BHVN)	United States	$1.990B	-3.83
Nuvation Bio Inc. (NUVB)	United States	$2.007B	-13.12
UroGen Pharma Ltd. (URGN)		$2.015B	-18.42
Zymeworks Inc. (ZYME)	United States	$1.902B	-12.44
NEKTAR THERAPEUTICS (NKTR)	United States	$2.026B	-9.05
PERRIGO Co plc (PRGO)	Ireland	$2.038B	-0.79
Generate Biomedicines, Inc. (GENB)	United States	$2.052B
Trevi Therapeutics, Inc. (TRVI)	United States	$2.091B	-51.93
PALVELLA THERAPEUTICS, INC. (PVLA)	United States	$2.105B	-35.55